Astatine-211—Tellurium Radiocolloid Cures Experimental Malignant Ascites
- 17 April 1981
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 212 (4492), 340-341
- https://doi.org/10.1126/science.7209534
Abstract
An investigation of the efficacy of astatine-211--tellurium colloid for the treatment of experimental malignant ascites in mice reveals that this alpha-emitting radiocolloid can be curative without causing undue toxicity to normal tissue. By comparison, negatron-emitting phosphorus-32 as colloidal chromic phosphate had no antineoplastic activity. The most compelling explanation for this striking difference is the dense ionization and short range of action associated with alpha-emission. These results have important implications for the development and use of alpha-emitters as radiocolloid therapy for the treatment of human tumors.This publication has 8 references indexed in Scilit:
- Limited epithelial carcinoma of the ovary treated with curative intent by the intraperitoneal installation of radiocolloidsCancer, 1978
- 5-125I-iododeoxyuridine as prototype for radionuclide therapy with Auger emittersNature, 1977
- Pathological Changes in Mice Following the Intraperitoneal Administration of RadionuclidesRadiology, 1974
- The Induction of Tumors in the Rat by Astatine-211Radiation Research, 1958
- Table of IsotopesReviews of Modern Physics, 1953
- Artificially Radioactive Element 85Physical Review B, 1940
- A Comparison of the Metabolism of Iodine and of Element 85 (Eka-Iodine)Proceedings of the National Academy of Sciences of the United States of America, 1940